| Scientific/Clinical Member Nominations Are Now Being Accepted for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents with HIV The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in antiretroviral therapy and the following areas: - HIV clinical research and clinical care
- Hepatitis B and hepatitis C infections
- Cost effectiveness and resource utilization
- Clinical pharmacology (with emphasis on drug-drug interactions)
- Biostatistics
Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 4-year term beginning April 2019, with potential for reappointment for an additional term.
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. The latest guideline was published on October 25, 2018, and can be found at https://aidsinfo.nih.gov/.
Panel members are not financially compensated for their time commitment.
The nomination should include a curriculum vitae and a letter of interest or a letter of nomination (from a colleague) with specific reference to how the nominee would contribute to the work of the Panel, especially in the areas noted above. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D., electronically (apau@niaid.nih.gov) by no later than January 15, 2019.
Nominations for New Scientific/Clinical Members for the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission in the U.S. The Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission in the United States (the Perinatal Guidelines Panel) is accepting nominations for new scientific/clinical members with expertise with pregnant women living with HIV and perinatal transmission. The Panel is seeking candidates with expertise in obstetrics/gynecology, pharmacology, pediatrics, and infectious disease studies in pregnant women.
Panel members critically evaluate new information and prepare guidelines revisions. The candidates shall be recognized experts in their areas of interest with a record of publications and presentations. The successful candidates shall serve a 3-year term beginning January 2019, with potential for reappointment. Because these are guidelines focused on the management of pregnant women living with HIV and perinatal transmission within the United States, candidates should be from the United States.
The Perinatal Guidelines Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, and HHS representatives with expertise in the management of pregnant women living with HIV (with training in either obstetrics/gynecology or women's health, or nursing with expertise in women's health) and interventions for perinatal transmission (such as pediatric specialists in HIV infection), as well as community representatives with knowledge of HIV infection in pregnant women and interventions for perinatal transmission.
The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in pregnant women and interventions for perinatal transmission to update the Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States, which is found at https://aidsinfo.nih.gov.
Panel members are not compensated for their time commitment.
The nomination should include a curriculum vitae and a letter of nomination or letter of interest with specific reference to how the nominee would contribute to the work of the Panel. Please submit nominations to Maria Nkwanzi, AIDSinfo Guidelines Coordinator, at maria.nkwanzi@icf.com. We are requesting that nominations be submitted by January 11, 2019.
Community Member Nominations Are Now Being Accepted for the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission in the U.S. The Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission in the United States (the Perinatal Guidelines Panel) is accepting nominations for a new community representative to serve a 3-year term beginning January 2019, with potential for reappointment for one additional term. Individuals who served as Panel members in the past are welcome to reapply. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents. The candidate shall have knowledge and involvement in issues related to the management of pregnant women living with HIV, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment.
The Perinatal Guidelines Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States.
Panel members are not compensated for their time commitment.
The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Maria Nkwanzi, AIDSinfo Guidelines Coordinator, at maria.nkwanzi@icf.com no later than January 11, 2019. | 
No comments:
Post a Comment